<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250106</url>
  </required_header>
  <id_info>
    <org_study_id>Probiotic-01</org_study_id>
    <nct_id>NCT01250106</nct_id>
  </id_info>
  <brief_title>Probiotics as a Novel Approach to Modulate Gut Hormone Secretion and Risk Factors of Type 2 Diabetes and Complications</brief_title>
  <official_title>Phase I Study of Probiotics as a Novel Approach to Modulate Gut Hormone Secretion and Risk Factors of Type 2 Diabetes and Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to test the hypothesis that Lactobacillus Reuteri-enriched microbiota
      improves insulin sensitivity and glucose tolerance in obese healthy and obese type 2 diabetes
      patients by improving gut hormone secretion and compare these findings to healthy lean
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prediabetes and diabetes are accompanied by insufficient gut hormone release, insulin
      resistance, insufficient insulin secretory capacity and low grade systemic inflammation.
      Results of recent animal experiments suggest that ingestion of probiotics not only influences
      gut microbiota composition and intestinal permeability but also secretion of GLP-2 as well as
      insulin resistance, components of metabolic syndrome and diabetes development. GLP-2
      secretion has been suggested to be a key mediator of probiotic effects mediating decreased
      intestine permeability through binding to intestinal GLP2 receptor in animal studies.
      Insulinotropic GLP-1, which is reduced in patients with type 2 diabetes, has also been
      described to be influenced by gut microbiota composition. We aim to test the hypothesis that
      Lactobacillus Reuteri-enriched microbiota improves insulin sensitivity and glucose tolerance
      in obese healthy and obese type 2 diabetes patients by improving gut hormone secretion. In a
      prospective, double-blinded, placebo controlled randomized 10 weeks trial we aim to
      investigate metabolic and immunological changes related to modified gut microbiota by
      analysing (1) gut hormone secretion, (2) insulin sensitivity and glucose tolerance, and (3)
      systemic LPS concentrations and immune status.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>gut hormones (GLP-1, GLP-2, GIP)</measure>
    <time_frame>8 and 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin secretion</measure>
    <time_frame>8 and 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of cytokines to define the immune status</measure>
    <time_frame>8 and 10 weeks</time_frame>
    <description>measurement and analysis of proinflammatory cytokines (Interleukin (IL)-6, tumor necrosis factor (TNF)-α, IL-1ß, Macropahge inflammatory protein (MIP)-1ß) and regulatory cytokines (IL-10, transforming growth factor (TGF)-ß, IL1ra) from peripheral blood samples collected during this trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>8 and 10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obesity</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Probiotic capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus reuteri</intervention_name>
    <description>twice daily</description>
    <arm_group_label>Probiotic capsule</arm_group_label>
    <arm_group_label>placebo capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese subjects: age 40 - 65 years, obesity (BMI 30-45 kg/m2), non-smoking, absence of
             gastrointestinal disease, willingness to abstain from intake of fermented milk
             products over a study period of 8 weeks.

          -  Healthy control subjects: non-obese (BMI 19-25 kg/m2), non-diabetic subjects, matched
             for age and sex, non-smoking, absence of gastrointestinal disease, willingness to
             abstain from intake of fermented milk products over a study period of 8 weeks.

        Exclusion Criteria:

          -  pregnancy, cancer, chronic diseases, antibiotic therapy, competitive athletes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nanette C Schloot, Priv.-Doz. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Diabetes Center, Duesseldorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nanette C Schloot, MD</last_name>
    <phone>+49 211 3382</phone>
    <phone_ext>665</phone_ext>
    <email>schloot@ddz.uni-duesseldorf.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Christine Simon, Dipl. oecotroph.</last_name>
    <phone>+49 211 3382</phone>
    <phone_ext>229</phone_ext>
    <email>marie-christine.simon@ddz.uni-duesseldorf.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>German Diabetes Center</name>
      <address>
        <city>Düsseldorf</city>
        <state>Duesseldorf</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nanette C Schloot, MD</last_name>
      <phone>+49 211 3382</phone>
      <phone_ext>665</phone_ext>
      <email>schloot@ddz.uni-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Marie-Christine Simon, Dipl. Oecotroph</last_name>
      <phone>+49 211 3382</phone>
      <phone_ext>229</phone_ext>
      <email>marie-christine.simon@ddz.uni-duesseldorf.de</email>
    </contact_backup>
    <investigator>
      <last_name>Nanette C. Schloot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <last_update_submitted>July 28, 2011</last_update_submitted>
  <last_update_submitted_qc>July 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Schloot, Nanette C.</name_title>
    <organization>German Diabetes Center</organization>
  </responsible_party>
  <keyword>probiotics</keyword>
  <keyword>prevention</keyword>
  <keyword>dietary intervention</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>obesity</keyword>
  <keyword>type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

